Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 833

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 833
---
 royalties equal to 5% of the Company’s revenues from product sales and the provision of drug scanning services, and 20% of the proceeds from the sale of sublicenses by the Company, as well as royalties at rates ranging from 2% to 7.5% for the sale of drug scanning products and additional receipts that the Company would receive from these products. In case the Company is obligated to pay royalties to another party in connection with the same product, the aforementioned royalty rate shall be reduced to 3.5%, 15%, and a rate ranging from 1.4% to 5.25%, respectively. On January 19, 2016, the Company entered into an addendum to the agreement with the third party, under which the Company would receive a non -exclusivelicense to use stem cells for the production of a cell therapy for ALS. The license also included scientific research to be carried out in third -partyresearch laboratories.

Annex G-30 KADIMASTEM LTD.
NOTES TO FINANCIAL STATEMENTS Note 17: — Contingent liabilities and COMMITMENTS (cont.) On March 24, 2020, the Company entered into an addendum to the agreement with the third party under which all the Company’s contracts became a non -exclusivelicense to use stem cells to create a cell therapy. In return, the rate of all royalties was reduced to 4% (compared to 5%) of product sales for a period of 15 years from the start of sales, and the payment for sublicenses was reduced to 15% (compared to 20%), provided that it does not fall below 1.25% of the sales. Since the Company has an agreement to pay royalties to an additional third party, in this case the royalty rates would be reduced from 4% to 2% of the product sales, and the payment for the sub -licenseswould be reduced to 10%. In addition, the Company would pay the aforementioned third party a payment for reaching milestones in the transplant product for the treatment of ALS according to the following rules: A.USD $150 thousand at the beginning of clinical phase IIb. B.USD $200 thousand at the beginning of clinical phase III. C.USD $2 million when obtaining a marketing license for a product to treat ALS in the US or Europe. In addition, the Company paid an annual license maintenance fee of USD $50 thousand until 2019, which was reduced to USD